Tuesday, Javelin Pharmaceuticals Inc. (JAV) said its third-quarter net loss attributable to common stockholders narrowed to $6.8 million or $0.11 per share from $10.9 million or $0.18 per share in the prior year period. On average, 3 analysts polled by Thomson Reuters expected the company to report a loss of $0.10 per share for the quarter.
Total revenues for the quarter rose to $1.13 million from $0.36 million in the comparable period. Analysts estimated revenues of $920.00 thousand for the quarter.
For comments and feedback: editorial@rttnews.com